The therapeutic landscape for metabolic disorders, and increasingly, a spectrum of other complex diseases, is undergoing a profound transformation, largely…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe inflammatory form, metabolic dysfunction-associated…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The therapeutic landscape for metabolic diseases has been irrevocably reshaped by the emergence of GLP-1 receptor agonists, a class of…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, metabolic dysfunction-associated steatohepatitis (MASH), a more serious inflammatory form of fatty liver disease, remained a largely overlooked condition,…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The therapeutic landscape for glucagon-like peptide-1 (GLP-1) receptor agonists has undergone a monumental transformation, extending far beyond its initial applications…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically its more severe inflammatory manifestation known as metabolic dysfunction-associated steatohepatitis (MASH), remained a significant…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The pharmaceutical landscape is undergoing a profound transformation, spearheaded by the remarkable expansion of Glucagon-Like Peptide-1 (GLP-1) receptor agonists. Initially…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, fatty liver disease, and its more severe inflammatory progression known as metabolic dysfunction-associated steatohepatitis (MASH), remained largely overlooked…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Neeraja Balachander, who oversees Boehringer Ingelheim’s extensive cardio-renal-metabolic portfolio, articulated the company’s ambitious vision. “We have a program in MASH,…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist.
For decades, metabolic dysfunction-associated steatohepatitis (MASH), the more severe inflammatory form of fatty liver disease, was a silent epidemic, often…
Read MoreYOU MAY HAVE MISSED
